Most eyelid tumours are benign, but a recurrent chalazion, a chronic unilateral blepharitis or a lesion with malignant signs needs tissue diagnosis rather than repeated drainage.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Classify the lesion before treating it
Eyelid lesions are common in oculoplastic practice, and most are benign. The clinical task is not to name every lesion from memory but to separate four groups: inflammatory or infectious disease, benign tumours, premalignant lesions and malignant tumours. That separation decides whether the next step is observation, medical treatment, excision or urgent biopsy. 1
The lecture lists the clinical signs that should raise concern: slow but steady growth, ulceration, a tendency to bleed, madarosis (loss of eyelashes), destruction of the meibomian gland orifices, telangiectasia and induration. A single sign is not proof of cancer, but the combination changes the plan. Look at the lid margin with magnification, evert the lid, and palpate the lesion rather than only photographing it. 1
The history matters as much as the appearance. Ask about previous skin cancer, cumulative sun exposure, radiotherapy, smoking and immunosuppression. Immunosuppressed patients, for example after organ transplantation, carry a markedly increased risk of squamous cell carcinoma; the lecture's figure of a 250-fold increase is an original claim that must be read in its selected context, not as a universal risk for every patient. 1
Chronic or recurrent disease deserves particular caution. A chalazion that keeps returning in the same place, a unilateral blepharitis that does not settle, or an eyelid “cyst” that regrows after drainage may be a sebaceous gland carcinoma, a tumour known as the great masquerader. The safe rule is to biopsy rather than to drain the same lesion repeatedly. 1
02Floppy eyelid syndrome and sleep apnoea
Floppy eyelid syndrome (FES) presents with foreign-body sensation, irritation, redness and discharge. On examination the upper and lower lids are markedly lax, the upper lid may droop, and the conjunctiva shows a papillary reaction. In severe cases the upper lid can fall over the lower lid, especially during sleep. 1
The lecture explains the mechanism as loss of elastin fibres in the tarsus, which makes the tarsal plate soft and excessively stretchable. The lid then fails to pump tears efficiently, and tearing results. This is a plausible clinical explanation and the lecture's model; it was not verified histologically in this review, so it should be presented as the proposed mechanism rather than a proven final pathway. 1
FES is strongly associated with obstructive sleep apnoea (OSA). The association is not itself a diagnosis, and eyelid surgery does not guarantee cure of OSA. Because untreated OSA can contribute to cardiac problems and pulmonary hypertension, ask about snoring, witnessed apnoeas, daytime sleepiness and morning headache, and refer for sleep assessment when the history suggests it. 1
Conservative treatment includes lubricating drops and ointments, antiallergic drops, short courses of topical steroid and protective shields during sleep. Surgical treatment tightens the lid, for example with a lateral tarsal strip procedure on the lower lid, similar to ectropion correction. On the upper lid a tarsal strip or wedge excision can be used; the speaker prefers a central or lateral excision to spare the lacrimal drainage system. The choice is individual and no single operation is universally best. 1
03Chalazion, hordeolum and the masqueraders
A chalazion is a sterile lipogranular inflammation caused by obstruction of a meibomian gland. It is an inflammation, not an infection. A hordeolum is an acute staphylococcal infection that blocks sebaceous glands: the Zeis glands externally and the meibomian glands internally. The distinction matters because the treatment and the expected course differ. 1
Every chalazion or hordeolum should raise the question of a malignant tumour, especially when it recurs, when it occurs in an older patient, when it is unilateral and persistent, or when the lid margin shows madarosis or destroyed gland orifices. The lecture calls sebaceous gland carcinoma the great masquerader because it is often misdiagnosed as a recurrent chalazion or chronic unilateral blepharitis. 1
For acute disease, warm compresses and lid hygiene are the most important measures. The speaker mentions tea tree oil for its anti-inflammatory properties, but the evidence is uncertain, it can irritate the ocular surface, and the lecture gives no instruction to apply it undiluted to the eye. It should not replace proven lid hygiene, and any product used near the eye needs a safe preparation and clear advice. 1 3
Oral doxycycline can be useful when the chalazion is associated with ocular rosacea. The lecture states that doxycycline is contraindicated in children under 8 years and in pregnancy, and names oral azithromycin as an alternative. That statement is bound to the ocular-rosacea context and the product label; it should not be generalised into a claim that every short doxycycline course is contraindicated in all such patients. Check the current label and the individual indication. 1
When intervention is needed, options are intralesional steroid injection or surgical incision and drainage. The speaker prefers dexamethasone over Kenalog (triamcinolone) because Kenalog can remain visible and may carry a higher risk of vascular occlusion. That is a speaker preference, not proof that dexamethasone is clinically superior; the choice depends on the lesion, the operator and the safety profile. 1
For incision and drainage, the incision is made transconjunctivally, from the inside of the lid. A vertical cut is preferred to spare neighbouring glands. The lecture says the lesion should be removed completely “including the capsule” to prevent recurrence. A chalazion is not a true cyst with a discrete capsule, so complete capsule removal cannot be guaranteed; what matters is adequate drainage, removal of the inspissated material and biopsy when the lesion is atypical or recurrent. 1
04Examination, epidemiology and when to biopsy
The history should cover previous skin cancers, the extent of sun exposure, radiotherapy, smoking and immunosuppression. These factors change the pretest probability and therefore the threshold for biopsy. A lesion in a sun-damaged fair-skinned older adult is not the same problem as a stable papule in a young patient. 1
The original cites more than 5000 Swiss eyelid tumours, 84% benign and 16% malignant, with about 90% BCC among malignant lesions. The located Deprez/Uffer abstract actually describes 5504 pathology cases from 1989–2007; 84% benign and 86% BCC among malignant tumours. Preserve the original approximation but distinguish the exact reported cohort result; referral and specimen selection prevent an individual probability estimate. 1 2
The lecture also states that a nevus of Ota carries an increased risk of uveal melanoma, with a figure of 1:400. That estimate comes from a selected population and should not be applied to every ancestry or every patient with periocular pigmentation. The practical point is to document the extent of pigmentation, examine the fundus and arrange surveillance when the diagnosis is credible, rather than to reassure or alarm on the basis of a single number. 1
Biopsy is the decisive step when malignancy is possible. A superficial shave may miss a deeper tumour, so the technique must match the suspected diagnosis. Sebaceous gland carcinoma needs a full-thickness biopsy, and because it can grow in skip lesions, multiple “map” biopsies may be needed to define the extent. Map biopsies are selected for suspected sebaceous carcinoma, not a routine for every eyelid lesion. 1
05Benign eyelid tumours
Benign epithelial hyperplasias include seborrhoeic keratosis, verruca vulgaris and fibroma molle, also called a skin tag. They are superficial lesions. Seborrhoeic keratosis and skin tags are usually treated for irritation or cosmetic reasons, while warts can be treated with cryotherapy; the lecture also mentions radiofrequency ablation. None of these should be treated blindly if the diagnosis is uncertain. 1
Benign epidermal lesions include the epidermal inclusion cyst, milia and molluscum contagiosum. The first two are cystic lesions, while molluscum is viral. The lecture recommends complete excision. In practice, molluscum often resolves spontaneously, especially in children, so observation can be appropriate; excision is a selected option, not an emergency. An inflamed or repeatedly infected cyst may need incision and drainage or excision. 1
Benign adnexal lesions in the lecture are xanthelasma, hidrocystoma and trichoepithelioma. Xanthelasma is a yellow plaque caused by lipid deposition in the dermis and is associated with high cholesterol; it is not a tumour of an adnexal gland, so it should not be classified as a primary adnexal neoplasm. Hidrocystoma arises from sweat glands, and trichoepithelioma from hair follicle structures. Treatment is usually surgical when the lesion is symptomatic or the diagnosis is uncertain. 1
Melanocytic lesions include nevus, ephelis (freckle), lentigo, blue nevus and nevus of Ota. Many are stable, but growth or change in colour, border or surface requires assessment. The lecture’s claim that nevi are the commonest benign lid lesion depends on the population; the Swiss series found papilloma most frequent. Ota-associated ocular pigmentation warrants individual ocular surveillance, not reassurance from a benign skin label. 1 2
The table groups the benign lesions into four categories and three columns, exactly as in the original. It is a teaching aid, not an exhaustive list, and it does not replace the examination. The fourth row is the one that needs the most caution, because pigmented lesions can be benign, premalignant or malignant, and the label “benign” is a diagnosis rather than an assumption. 1
| Category | Types | Features and treatment |
|---|---|---|
| Epithelial hyperplasias | Seborrhoeic keratosis, verruca vulgaris (wart), fibroma molle (skin tag) | Selected radiofrequency/cryotherapy after a secure diagnosis; stable lesions may be observed. |
| Benign epidermal lesions | Epidermal inclusion cyst, milia, molluscum contagiosum | Cystic or viral lesions: excision is selected, not mandatory for every lesion; assess irritation and diagnosis. |
| Benign adnexal lesions | Xanthelasma, hidrocystoma, trichoepithelioma | Hidrocystoma/trichoepithelioma arise from appendages; xanthelasma is dermal lipid deposition, not an adnexal neoplasm. Cholesterol may be normal. Treat when indicated. |
| Benign melanocytic lesions | Nevus (mole), ephelis (freckle), lentigo, blue nevus, nevus of Ota | Many stable nevi need observation; the original Ota1:400 uveal melanoma estimate is population-specific and not a universal risk. |
06Premalignant lesions and in-situ disease
Actinic keratosis is a common sun-related keratinocytic lesion, often rough like sandpaper. It can progress to squamous carcinoma, but neither a universally low annual rate nor a universally high cumulative rate follows from the original. Excision or selected topical 5-fluorouracil (5-FU) depends on diagnosis, extent and periocular safety; exclude invasion before choosing a surface treatment. 1
Bowen disease is squamous carcinoma in situ. Excision with margin assessment is an important option, especially when invasion is uncertain, but it is not the only possible treatment in every patient. Histology, site, extent and specialist assessment determine a surgical or selected non-surgical plan and follow-up. 1
Keratoacanthoma typically grows rapidly with a central keratin plug and crater-like shape. Its classification overlaps with squamous carcinoma and remains debated; the original low-grade-SCC label is not universal consensus. Treat a suspicious lesion with appropriate histology and usually excision rather than assuming spontaneous regression is safe. 1
Lentigo maligna is not merely a precancer: it is melanoma in situ. It presents as an irregularly bordered, unevenly pigmented macule on sun-damaged skin, often in older patients. The lecture calls it a precancer of malignant melanoma, but the more accurate modern description is in-situ melanoma. Complete excision with margin control is needed, and any invasive component changes staging and management. 1 4
07Malignant eyelid tumours
BCC is a major malignant eyelid tumour, often on the lower lid or medial canthus, followed by upper and lateral sites in the lecture’s teaching order. Original 90% is a context-dependent approximation; the Swiss abstract reports 86%. UV exposure and fair skin are important, while the original smoking claim is not independently established here as a universal BCC risk. Mohs or other margin-controlled excision is selected according to site, tumour and service expertise. 1 2
Squamous cell carcinoma is less common than basal cell carcinoma but more aggressive and has metastatic potential. The lecture states that the risk is increased 250-fold in immunosuppressed patients. That figure belongs to a selected transplant and immunosuppression context and should be quoted with its limitation; it is not a universal multiplier for every patient. Treatment is wide surgical excision, with margin assessment and specialist oculoplastic involvement. 1
Sebaceous gland carcinoma is the great masquerader. It is often misdiagnosed as a recurrent chalazion or chronic unilateral blepharitis. It occurs more often on the upper lid because there are more meibomian glands there. Diagnosis requires a full-thickness biopsy, and because of skip lesions, multiple map biopsies may be needed to determine the extent. It is an aggressive tumour with a high metastatic risk. 1
The lecture describes sebaceous gland carcinoma as radioresistant. That absolute statement is not supported as a universal rule; radiotherapy can have a role in selected cases, and the decision belongs to the multidisciplinary tumour board. The safe conclusion is that surgery is the main treatment and that radiotherapy is individualised, not that the tumour never responds to radiation. 1
The original lecture reports eyelid melanoma as less than1% of malignant eyelid tumours; this proportion is cohort-dependent. Malignant melanoma of the eyelid is very rare, less than 1 % of malignant eyelid tumours. The decisive prognostic factor is vertical invasion depth, the Breslow thickness. The lecture states that lesions deeper than 4 mm have a 5-year survival below 50 %. That figure comes from the original context and is not a universal current risk; staging, ulceration, mitotic rate and nodal status also matter. Treatment is wide local excision, and sentinel lymph node biopsy is selected according to staging rather than mandatory for every patient. 1
Kaposi sarcoma is a reddish-violet lesion lying deep in the dermis and is associated with HIV/AIDS. Merkel cell carcinoma is a rare but very aggressive neuroendocrine tumour with a high recurrence and metastasis rate; it requires wide excision and often adjuvant radiotherapy. These tumours are uncommon, but they belong in the differential because the eyelid is a visible site and early recognition changes the treatment pathway. 1
Metastatic tumours and other rare lesions can also involve the eyelid, and a lesion that does not fit the common patterns should not be forced into a benign category. The practical approach is to document size, colour, border, surface, mobility and relation to the lid margin, to examine the regional lymph nodes, and to biopsy when the diagnosis is uncertain. 1
08What to do next and what to say
The safe sequence is to classify the lesion, look for the signs of malignancy, and biopsy when the diagnosis is uncertain or the lesion recurs. Do not repeatedly drain a chalazion in the same place, and do not treat a chronic unilateral blepharitis with repeated courses of drops without examining the lid margin and considering a tumour. 1
Explain the working diagnosis, the uncertainty and the specific return signs: growth, ulceration, bleeding, loss of lashes, a new lump in the neck, or a lesion that does not heal. Document the reasoning and the biopsy result so the next clinician can continue safely. For benign lesions, say plainly that they are usually harmless, but that change needs reassessment rather than reassurance alone. 1
The lecture gives useful numbers and treatment preferences, but they come from a selected clinical experience and a selected cohort. Use them to organise thinking, verify the individual diagnosis, and let the histology and the patient's context decide the final plan. The educational text does not replace a personal examination or a multidisciplinary decision. 1
What are the main learning points?
Most eyelid tumours are benign, but a recurrent chalazion, a chronic unilateral blepharitis or a lesion with malignant signs needs tissue diagnosis rather than repeated drainage.
When is assessment urgent?
A lesion with ulceration, bleeding, madarosis, induration or destroyed meibomian orifices, and a recurrent chalazion or non-healing eyelid ulcer, need urgent specialist assessment and biopsy.
References and access status
- 1Immutable original export; attributed in the export to Dr Lamis Rajjoub; attribution unverified
Complete original lecture text and inventory read locally; external GitHub page, recording, transcript and attribution not independently verified.
- 2Deprez and Uffer. Swiss eyelid tumour series 2009
Complete abstract read: retrospective 5504 pathology cases 1989–2007;84%benign,86%of malignant lesions BCC. Selected laboratory series, not population incidence. Main article unread.
- 3Savla et al. Tea tree oil for Demodex blepharitis. Cochrane 2020
Official summary, methods, results and conclusions read:6 RCTs 562 participants, variable protocols/high or unclear bias; uncertain efficacy, irritation possible. Not a chalazion-specific efficacy trial.
- 4International Dermoscopy Society consensus: lentigo maligna
Retrieved definition excerpt identifies lentigo maligna as melanoma in situ; direct PMC full text blocked by challenge. No claim to have read full management recommendations.
For patients
This chapter explains how clinicians distinguish common inflammatory eyelid disease from benign, premalignant and malignant eyelid tumours, and when a tissue diagnosis is needed.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
A lesion with ulceration, bleeding, madarosis, induration or destroyed meibomian orifices, and a recurrent chalazion or non-healing eyelid ulcer, need urgent specialist assessment and biopsy.
A lesion with ulceration, bleeding, madarosis, induration or destroyed meibomian orifices, and a recurrent chalazion or non-healing eyelid ulcer, need urgent specialist assessment and biopsy.